Health
GLP-1 Side Effects and Who Should Not Take Them
Nausea is the least of it. Here is an honest look at GLP-1 side effects, the thyroid warning, pancreatitis and who is advised to avoid them.
Jul 10, 2024
Loading
Search
Results
12 stories for“glp-1 side effects”
Health
The GLP-1 Era: How Weight-Loss Drugs Changed Us
Semaglutide and tirzepatide went from diabetes treatment to celebrity shortcut to a genuine health story. What happens when one drug becomes a cultural moment.
Apr 20, 2024
Health
One Receptor, Two, or Three: Comparing Semaglutide, Tirzepatide and Retatrutide
Ozempic, Mounjaro and the drug that has not arrived yet are not three versions of the same thing. They hit different receptors, produce different results, and suit different people.
Aug 11, 2026
Health
Mounjaro and Zepbound: The Case for Two Hormones at Once
Tirzepatide just beat semaglutide head to head in a major trial. Here is what SURMOUNT and SURPASS data actually shows about hitting two receptors.
Dec 9, 2024
Health
Retatrutide: The Triple Agonist Still Proving Itself
Retatrutide just posted phase 3 weight loss data hitting three hormone receptors at once. Here is what is confirmed and what remains unproven.
May 27, 2026
Health
Ozempic in a Tablet: What the Rebrand of Oral Semaglutide Actually Changes
Novo Nordisk folded Rybelsus into the Ozempic name in May and put a self-pay price on it. Getting a peptide to survive the stomach is a real achievement, but the tablet is not simply the injection in another form.
Aug 11, 2026
Health
Berberine and the 'Nature's Ozempic' Claim: What Evidence Shows
Berberine lowers cholesterol and blood sugar in small trials, but comparing it to semaglutide misreads both the data and the biology.
Feb 14, 2024
Health
Retatrutide's Third Receptor Is the Hormone That Raises Blood Sugar. Adding It On Purpose Is the Whole Idea
Semaglutide hits one receptor and tirzepatide hits two. The third one retatrutide adds is glucagon, which does the opposite of what a diabetes drug is supposed to do. It is also where the liver results and the safety questions both come from.
Aug 20, 2026
Health
Retatrutide's Phase 3 Run Is Nearly Complete. The Numbers Are the Largest Yet
TRIUMPH-2 and TRIUMPH-3 read out in July, following TRIUMPH-1 in May. Across the programme the triple agonist has produced weight loss in a range no approved obesity drug has reached, with a filing due in early 2027.
Aug 11, 2026
Health
What a Peptide Actually Is, and Why the Word Now Sells Almost Anything
Insulin is a peptide. So is Ozempic. So is the unlabelled vial someone is selling on Telegram. The word describes a chemical class, not a level of evidence, and that gap is where the market lives.
Aug 11, 2026
Health
Ozempic and Wegovy: What the Trials Actually Showed
Semaglutide now has a heart disease approval too. Here is what the STEP and SELECT trial data really says, and what it does not.
Mar 13, 2024
